How Should Botulinum Toxin Type A Products Be Compared?

A meaningful comparison should begin with a specific clinical question and use evidence that directly addresses that question.

Botulinum toxin type A products belong to the same pharmacologic class, but this does not make them identical medicines.

Products may differ in:

• manufacturing processes;

• formulation and excipients;

• neurotoxin preparation;

• potency assays;

• labeled units;

• approved indications;

• dosing instructions;

• storage and preparation requirements; and

• amount and quality of product-specific clinical evidence. [1–3]

For this reason, a comparison based only on marketing terms such as “strongest,” “purest,” “longest-lasting,” “most precise” or “best” can be misleading unless the claim is linked to an appropriate measurement and supporting evidence.

Step 1: Define the Clinical Question Before Comparing Products

“Which toxin is better?” is not a sufficiently precise scientific question.

A useful comparison must first specify what is being compared.

For example:

Which products have randomized comparative evidence for glabellar lines?

is different from:

Which products have clinical evidence in post-stroke upper-limb spasticity?

Likewise:

Which product showed a faster patient-reported onset in a particular trial?

is different from:

Which product has a longer follow-up period in published studies?

Without a defined question, evidence from unrelated indications and endpoints can easily be mixed together.

Step 2: Confirm the Exact Products

A comparison should identify the exact products rather than use “Botox” as a generic term for the entire BoNT-A class.

Important information includes:

• brand name;

• active substance or recognized nonproprietary name where applicable;

• strength and presentation;

• manufacturer;

• jurisdiction;

• current approved product information; and

• registration or authorization status.

This prevents evidence from one product from being unintentionally attributed to another.

Step 3: Separate Regulatory Facts From Research Findings

Regulatory documents and clinical papers answer different questions.

Product information should be used for facts such as:

• approved indications;

• labeled dose;

• contraindications;

• warnings;

• storage;

• reconstitution;

• administration; and

• regulatory product identity.

Clinical studies should be used to evaluate:

• efficacy;

• comparative efficacy;

• clinical response;

• duration under the study design;

• adverse events;

• study populations; and

• statistical conclusions.

A clinical paper does not automatically establish local regulatory approval.

Similarly, an approved indication should not be reduced to the findings of one publication.

Step 4: Do Not Assume That Units Are Interchangeable

BoNT-A potency units are biological activity units rather than conventional mass measurements.

Different products may use product-specific potency assays and reference standards. [1,2]

Therefore:

100 U of product A should not automatically be interpreted as biologically or clinically identical to 100 U of product B.

A numerical dose ratio tested in a clinical trial is evidence for that particular protocol.

It is not automatically a universal conversion factor.

Step 5: Formulation Differences Are Real—but Do Not Overinterpret Them

Products can differ in formulation, excipients, manufacturing and neurotoxin preparation. [1–3]

These differences are legitimate product characteristics.

However, formulation information alone does not prove that one product is:

• more effective;

• safer;

• longer-lasting;

• less likely to diffuse;

• more precise;

• less immunogenic; or

• clinically superior.

Those are clinical claims and require appropriate clinical evidence.

A formulation comparison should therefore remain a formulation comparison unless clinical outcomes have actually been studied.

Step 6: Prefer Direct Comparative Clinical Evidence

When comparing two named products, a randomized head-to-head trial in the relevant indication is especially informative.

A direct comparative trial allows the products to be studied under a common protocol with defined:

• population;

• dose;

• injection procedure;

• comparator;

• endpoint;

• follow-up schedule; and

• statistical analysis.

This reduces—but does not eliminate—the uncertainty involved in comparing results from separate studies.

Why Are Separate Trials Harder to Compare?

Suppose product A has a 90% response rate in one study and product B has an 85% response rate in another.

It is not scientifically valid to conclude that product A is better solely from those numbers.

The trials may differ in:

• patient severity;

• response definition;

• dose;

• injection technique;

• assessment timing;

• investigator scale;

• statistical population; and

• follow-up.

Cross-trial numerical comparisons therefore require substantial caution.

Step 7: Read the Primary Endpoint

The primary endpoint is central to understanding what a trial was designed to demonstrate.

Ask:

What exactly was measured?

Who assessed it?

At what time point?

How was response defined?

Was the endpoint prespecified?

For example, in the Neuronox glabellar Phase III study, the primary endpoint was an investigator-assessed responder rate at maximum frown at week 4. [4]

Neuronox/NBoNT showed a responder rate of 93.7%, compared with 94.5% for onabotulinumtoxinA, and the prespecified non-inferiority criterion was met. [4]

The correct conclusion is about that endpoint under that protocol.

It is not a universal conclusion that every outcome of the two products is identical.

Step 8: Understand What Non-Inferiority Means

Several Neuronox comparative trials used non-inferiority designs.

A non-inferiority trial asks whether the test treatment is not worse than the comparator by more than a predefined acceptable margin for the primary endpoint.

If the criterion is met, the correct interpretation is:

non-inferiority was demonstrated according to the prespecified margin and endpoint.

It does not mean:

the products are identical

or

the test product is superior.

The margin, confidence interval and analysis population should therefore be reviewed rather than reading only the word “non-inferior.”

Step 9: Read the Actual Numbers Behind the Conclusion

The statistical conclusion is important, but so are the underlying results.

For Neuronox, product-specific randomized comparative evidence includes several distinct settings.

Glabellar Lines

In a Phase III randomized, double-blind study of 314 participants:

Neuronox/NBoNT: 93.7% week-4 responder rate

onabotulinumtoxinA: 94.5%

The prespecified non-inferiority criterion was met. [4]

Essential Blepharospasm

In the randomized comparative trial:

Meditoxin/Neuronox: 90.3% improvement

BOTOX: 86.2%

The lower confidence limit remained above the prespecified −15% non-inferiority margin in both ITT and PP analyses. [5]

This demonstrated non-inferiority under the studied protocol.

It did not establish superiority.

Cerebral-Palsy Spastic Equinus

At week 12, the ITT Physicians' Rating Scale response rates were:

Neuronox: 48.3%

BOTOX: 49.2%

The lower confidence limit remained within the prespecified −20% margin, and non-inferiority was demonstrated. [6]

Post-Stroke Upper-Limb Spasticity

At week 4, change in wrist-flexor Modified Ashworth Scale was:

Neuronox: −1.39 ± 0.79

BOTOX: −1.56 ± 0.81

The upper confidence limit for the treatment difference was 0.40, below the prespecified non-inferiority margin of 0.45. [7]

Again, the primary analysis met the trial's non-inferiority criterion.

What Does This Evidence Allow Us to Say About Neuronox?

A strong evidence-based statement is:

Neuronox has published randomized comparative clinical evidence across multiple aesthetic and therapeutic settings, and the primary analyses of the four reviewed studies met their respective prespecified non-inferiority criteria. [4–7]

That is a meaningful product-specific evidence statement.

It does not require claims that Neuronox is “better,” “stronger” or universally interchangeable with its comparators.

Step 10: Do Not Compare Efficacy Percentages Across Different Indications

The 93.7% glabellar responder rate and 48.3% cerebral-palsy PRS response rate cannot be compared as though one represented better performance.

They come from:

• different diseases;

• different muscles;

• different populations;

• different doses;

• different endpoints; and

• different definitions of response.

Percentages only have meaning within their study context.

Step 11: Examine Secondary Outcomes Without Cherry-Picking

Secondary outcomes can provide useful clinical detail.

However, one statistically significant secondary result should not automatically be presented as proof of overall product superiority.

For example, the post-stroke Neuronox study reported a between-group difference in elbow-flexor MAS at week 12.

That isolated secondary finding does not change the overall trial into a superiority study. [7]

A balanced review should report the primary endpoint first and then describe relevant secondary outcomes in context.

Step 12: Compare Safety With the Same Caution

Safety should not be reduced to a simple statement such as:

“Product A had fewer adverse events, therefore it is safer.”

Trials may not be powered to detect safety differences.

Rare events may not appear in relatively small studies.

Adverse-event definitions, populations, doses and follow-up also vary.

For example, in the Neuronox blepharospasm study, adverse events occurred in 16.1% of the Meditoxin group and 27.6% of the BOTOX group, but the difference was not statistically significant. [5]

Therefore, the study does not establish that Neuronox is safer.

Similarly, in the cerebral-palsy trial, adverse events occurred in nine children in each group, with no significant between-group difference. [6]

The appropriate conclusion is based on the statistical evidence, not the visually smaller number.

Step 13: Duration Must Be Defined Before It Is Compared

A study with follow-up to 24 weeks does not automatically prove longer duration than a study ending at 12 weeks.

Duration may be measured as:

• persistence of response;

• time to loss of response;

• time to retreatment;

• response at a scheduled visit; or

• another prespecified endpoint.

The study's last visit should not automatically be treated as the product's duration.

Step 14: “Diffusion” Claims Need Direct Evidence

Statements such as:

“spreads less”

“stays exactly where injected”

or

“has the widest diffusion”

should not be inferred from formulation alone.

Clinical spread is influenced by multiple factors, including dose, injection volume, location, anatomy and technique.

If diffusion or field of effect is the comparison question, the study must actually measure a relevant outcome under a controlled design.

The four core Neuronox randomized comparative trials were primarily efficacy and safety studies.

They should not be converted into evidence that Neuronox has a uniquely lower or higher diffusion profile.

Step 15: Immunogenicity Claims Also Need Specific Evidence

“No antibodies detected in this study” does not mean “this product cannot cause neutralizing antibodies.”

Immunogenicity depends on:

• exposure;

• dose;

• treatment frequency;

• follow-up duration;

• assay;

• patient population; and

• other factors.

A product comparison should report exactly what was measured rather than turn a negative antibody result into a universal immunity claim.

Step 16: Consider Study Quality

Not all papers carry the same evidentiary weight.

Important features include:

• randomization;

• blinding;

• active or placebo control;

• adequate sample size;

• predefined primary endpoint;

• predefined statistical margin;

• intention-to-treat analysis;

• per-protocol analysis when appropriate;

• multicentre design;

• duration of follow-up;

• validated assessment methods; and

• complete safety reporting.

A randomized controlled comparative trial generally provides more useful comparative evidence than an uncontrolled case series when the question is how two named products compare.

Step 17: Preserve Sponsorship and Conflict-of-Interest Information

Industry involvement does not automatically invalidate a study.

However, sponsorship and author relationships are relevant to transparent evidence appraisal.

When a paper reports:

• manufacturer funding;

• employee authorship;

• consultancy;

• lecture honoraria; or

• other conflicts,

these should not be removed from an evidence summary.

The reader should be able to evaluate both the study methods and the disclosure context.

Step 18: Do Not Turn the Evidence Into a Star Rating

A table assigning:

★★★★★ efficacy

★★★★★ safety

★★★★ diffusion

may look simple but can hide major methodological problems.

What scale produced the score?

Were different indications combined?

How were endpoints weighted?

Were safety and efficacy given equal weight?

Were studies randomized?

Was evidence quality considered?

Unless a validated and transparent methodology exists, star ratings can create a false sense of scientific precision.

A Better Comparison Framework

For each BoNT-A product, compare the following domains separately:

Product Identity

Exact brand, presentation, manufacturer and regulatory jurisdiction.

Regulatory Evidence

Current approved indications, warnings and labeled instructions.

Formulation

Active preparation, excipients and presentation—without automatically converting differences into clinical claims.

Potency Units

Treat units as product-specific.

Clinical Evidence

Identify randomized controlled and direct comparative studies.

Study Population

Specify who was actually studied.

Dose and Injection Protocol

Report the trial-specific dose rather than assume universal conversion.

Primary Endpoint

Identify exactly what the study was designed to test.

Statistical Design

Superiority, equivalence or non-inferiority should not be treated as interchangeable concepts.

Follow-Up

Report actual assessment periods without turning them automatically into duration claims.

Safety

Report adverse events and serious adverse events in context.

Immunogenicity

State assay method, exposure and follow-up where available.

Funding and Conflicts

Preserve reported disclosures.

Why Is Neuronox Particularly Suitable for an Evidence-First Comparison?

Because Neuronox does not need to be positioned only through formulation comparisons or marketing descriptors.

There are published randomized comparative clinical trials evaluating the product in:

glabellar lines [4]

essential blepharospasm [5]

cerebral-palsy-associated spastic equinus [6]

and

post-stroke upper-limb spasticity. [7]

This means a Neuronox comparison can begin with actual product-specific human clinical data.

The four studies differ in population, dosing and endpoint, so they should not be pooled into one efficacy percentage.

But together they demonstrate that Neuronox has been prospectively compared with an active comparator across several clinical settings.

What Is the Strongest Neuronox Message Supported by This Evidence Set?

Not:

“Neuronox is the best toxin.”

Not:

“Neuronox is stronger than BOTOX.”

Not:

“Neuronox is identical to BOTOX.”

The stronger scientific message is:

Neuronox has product-specific published randomized comparative evidence in multiple aesthetic and therapeutic settings, with the primary analyses of the reviewed studies meeting their respective prespecified non-inferiority criteria. [4–7]

That statement is specific, clinically meaningful and traceable to published evidence.

Frequently Asked Questions

Does similar formulation prove two BoNT-A products are clinically equivalent?

No. Clinical equivalence or non-inferiority requires appropriately designed clinical evidence.

Does the same number of Units mean the same dose across brands?

Not automatically. BoNT-A units should be treated as product-specific.

Does non-inferiority mean the products are identical?

No.

Can a lower adverse-event percentage prove a product is safer?

Not unless the study supports a statistically and clinically valid safety comparison.

Can longer study follow-up prove longer duration?

Not by itself.

What is the most useful evidence for comparing two named products?

A well-designed direct comparative study in the relevant indication, interpreted together with current product information.

Can Neuronox be compared using direct clinical evidence?

Yes. Published randomized comparative studies exist in several aesthetic and therapeutic clinical settings. [4–7]

Bottom Line

A scientifically meaningful BoNT-A comparison should not begin with marketing adjectives.

It should begin with:

the exact product

the clinical question

the relevant indication

the labeled information

the dose and protocol

the primary endpoint

the statistical design

the clinical results

the safety data

and

the quality of the evidence.

For Neuronox, an important strength is the existence of product-specific randomized comparative clinical evidence across multiple settings.

The evidence does not establish universal superiority or interchangeability.

It does allow a much stronger statement than a marketing slogan:

Neuronox has been directly evaluated in published randomized comparative clinical trials, and the primary analyses of the four reviewed studies met their prespecified non-inferiority criteria.

That is the type of comparison an evidence-based reference should prioritize.

References

1. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227–241. doi:10.2147/BTT.S65603. PMID:25336912.

2. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;13(Suppl 1):2–10.

3. Pickett A, Perrow K. Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol. 2010;9(9):1085–1091.

4. Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072. PMID:23301821.

5. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137. PMID:19794937.

6. Kim K, Shin HI, Kwon BS, Kim SJ, Jung IY, Bang MS. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x. PMID:21087238.

7. Seo HG, Paik NJ, Lee SU, Oh BM, Chun MH, Kwon BS, Bang MS. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633. PMID:26030192.

8. NEURONOX Thai Product Information. Revised April 3, 2023.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.